Systemic delivery of nanoparticle formulation of novel tubulin inhibitor for treating metastatic melanoma

Drug Delivery and Translational Research

Volumn 5, Issue 3, 2015, Pages 199-208

  Mundra, Vaibhav ^a   Peng, Yang ^a   Kumar, Virender ^a   Li, Wei ^b   Miller, Duane D ^b   Mahato, Ram I ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

Lung metastasis; Metastatic melanoma; Nanoparticles; Tubulin inhibitor

Indexed keywords

ANTINEOPLASTIC AGENT; COPOLYMER; KI 67 ANTIGEN; LY 293; METHOXY POLYEHTYLENE GLYCOL B POLY(CARBONATE CO LACTIDE) COPOLYMER; NANOCARRIER; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; WATER OIL CREAM; 2-(1H-INDOL-5-YL)THIAZOL-4-YL) 3,4,5-TRIMETHOXYPHENYL METHANONE; DRUG CARRIER; INDOLE DERIVATIVE; MACROGOL DERIVATIVE; METHOXY POLYETHYLENE GLYCOL-B-POLY(CARBONATE-CO-LACTIDE); NANOPARTICLE; POLYESTER; THIAZOLE DERIVATIVE; TUBULIN MODULATOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER SIZE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; EMULSION; ENCAPSULATION; FLOW CYTOMETRY; GEL PERMEATION CHROMATOGRAPHY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; LUNG METASTASIS; LUNG PARENCHYMA; MELANOMA CELL; METASTATIC MELANOMA; MICROTUBULE ASSEMBLY; MITOSIS; MITOSIS INHIBITION; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SYNTHESIS; SYSTEMIC THERAPY; WEIGHT REDUCTION; ANIMAL; C57BL MOUSE; CELL CYCLE G2 PHASE; CHEMISTRY; DRUG EFFECTS; INTRAVENOUS DRUG ADMINISTRATION; LUNG; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; METABOLISM; PATHOLOGY; SECONDARY; SKIN NEOPLASMS; SOLUBILITY; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; DRUG CARRIERS; DRUG COMPOUNDING; G2 PHASE; HUMANS; INDOLES; INJECTIONS, INTRAVENOUS; LUNG; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE, INBRED C57BL; NANOPARTICLES; PARTICLE SIZE; POLYESTERS; POLYETHYLENE GLYCOLS; SKIN NEOPLASMS; SOLUBILITY; THIAZOLES; TUBULIN MODULATORS; TUMOR BURDEN;

EID: 84928893366     PISSN: 2190393X     EISSN: 21903948     Source Type: Journal    
DOI: 10.1007/s13346-015-0226-2     Document Type: Article

References (31)

1. Bhatia S, Tykodi SS, Thompson JA. Treatment of metastatic melanoma: an overview. Oncology (Williston Park). 2009;23:488–96.
2. Gray-Schopfer V, Wellbrock C, Marais R. Melanoma biology and new targeted therapy. Nature. 2007;445:851–7.
3. Dummer R, Flaherty KT. Resistance patterns with tyrosine kinase inhibitors in melanoma: new insights. Curr Opin Oncol. 2012;24:150–4.
4. Sun C, Wang L, Huang S, Heynen GJ, Prahallad A, Robert C, et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature. 2014;508:118–22.
5. Hersh EM, O’Day SJ, Ribas A, Samlowski WE, Gordon MS, Shechter DE, et al. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Cancer. 2010;116:155–63.
6. Chang W, Lee SJ, Park S, Choi MK, Hong JY, Kim YS, et al. Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma. Melanoma Res. 2013;23:147–51.
7. Lu Y, Li CM, Wang Z, Ross 2nd CR, Chen J, Dalton JT, et al. Discovery of 4-substituted methoxybenzoyl-aryl-thiazole as novel anticancer agents: synthesis, biological evaluation, and structure-activity relationships. J Med Chem. 2009;52:1701–11.
8. Lu Y, Li CM, Wang Z, Chen J, Mohler ML, Li W, et al. Design, synthesis, and SAR studies of 4-substituted methoxylbenzoyl-aryl-thiazoles analogues as potent and orally bioavailable anticancer agents. J Med Chem. 2011;54:4678–93.
9. Lu Y, Chen J, Xiao M, Li W, Miller DD. An overview of tubulin inhibitors that interact with the colchicine binding site. Pharm Res. 2012;29:2943–71.
10. Wang Z, Chen J, Wang J, Ahn S, Li CM, Lu Y, et al. Novel tubulin polymerization inhibitors overcome multidrug resistance and reduce melanoma lung metastasis. Pharm Res. 2012;29:3040–52.
11. ten Bokkel Huinink WW, Eisenhauer E, Swenerton K. Preliminary evaluation of a multicenter, randomized comparative study of TAXOL (paclitaxel) dose and infusion length in platinum-treated ovarian cancer. Canadian-European Taxol Cooperative Trial Group. Cancer Treat Rev. 1993;19(Suppl C):79–86.
12. Hamaguchi T, Kato K, Yasui H, Morizane C, Ikeda M, Ueno H, et al. A phase I and pharmacokinetic study of NK105, a paclitaxel-incorporating micellar nanoparticle formulation. Br J Cancer. 2007;97:170–6.
13. Danquah M, Li F, Duke 3rd CB, Miller DD, Mahato RI. Micellar delivery of bicalutamide and embelin for treating prostate cancer. Pharm Res. 2009;26:2081–92.
14. Danquah M, Fujiwara T, Mahato RI. Self-assembling methoxypoly(ethylene glycol)-b-poly(carbonate-co-L-lactide) block copolymers for drug delivery. Biomaterials. 2010;31:2358–70.
15. Gaucher G, Marchessault RH, Leroux JC. Polyester-based micelles and nanoparticles for the parenteral delivery of taxanes. J Control Release. 2010;143:2–12.
16. Danquah MK, Zhang XA, Mahato RI. Extravasation of polymeric nanomedicines across tumor vasculature. Adv Drug Deliv Rev. 2011;63:623–39.
17. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65:271–84.
18. Mundra V, Lu Y, Danquah M, Li W, Miller DD, Mahato RI. Formulation and characterization of polyester/polycarbonate nanoparticles for delivery of a novel microtubule destabilizing agent. Pharm Res. 2012;29:3064–74.
19. Nederberg F, Lohmeijer BG, Leibfarth F, Pratt RC, Choi J, Dove AP, et al. Organocatalytic ring opening polymerization of trimethylene carbonate. Biomacromolecules. 2007;8:153–60.
20. Lohmeijer B, Pratt RC, Leibfarth F, Logan JW, Long DA, Dove AP, et al. Guanidine and amidine organocatalysts for ring-opening polymerization of cyclic esters. Macromolecules. 2006;39:8574–83.
21. Tas F. Metastatic behavior in melanoma: timing, pattern, survival, and influencing factors. J Oncol. 2012;2012:647684.
22. Soengas MS, Lowe SW. Apoptosis and melanoma chemoresistance. Oncogene. 2003;22:3138–51.
23. Frank NY, Margaryan A, Huang Y, Schatton T, Waaga-Gasser AM, Gasser M, et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 2005;65:4320–33.
24. La Porta CA. Drug resistance in melanoma: new perspectives. Curr Med Chem. 2007;14:387–91.
25. Li CM, Chen J, Lu Y, Narayanan R, Parke DN, Li W, et al. Pharmacokinetic optimization of 4-substituted methoxybenzoyl-aryl-thiazole and 2-aryl-4-benzoyl-imidazole for improving oral bioavailability. Drug Metab Dispos. 2011;39:1833–9.
26. Dahan A, Sabit H, Amidon GL. Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of p-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine. Drug Metab Dispos. 2009;37:2028–36.
27. Dahan A, Amidon GL. Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein. Pharm Res. 2009;26:883–92.
28. Kamber NE, Jeong W, Waymouth RM, Pratt RC, Lohmeijer BG, Hedrick JL. Organocatalytic ring-opening polymerization. Chem Rev. 2007;107:5813–40.
29. Bero M, Czapla B, Dobrzynski P, Janeczek H, Kasperczyk J. Copolymerization of glycolide and ε-caprolactone, 2. random copolymerization in the presence of tin octoate. Macromol Chem Phys. 1999;200:911–6.
30. Seow WY, Yang YY. Functional polycarbonates and their self-assemblies as promising non-viral vectors. J Control Release. 2009;139:40–7.
31. Maeda H, Bharate GY, Daruwalla J. Polymeric drugs for efficient tumor-targeted drug delivery based on EPR-effect. Eur J Pharm Biopharm. 2009;71:409–19.